Richard Smith on Muck Rack

Richard Smith

Clapham, London
As seen in: BBC, The Daily Mirror, The Guardian, TIME, Washington Post Opinions, New York Daily News, PLOS, The Wall Street Journal, BMJ Open, POLITICO and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Q&A: What it takes to run a culinary camp for children with CKD

|
By Lucas Laboy, Sandra P. Amaral, Richard Smith
| Citeline Verified
Key takeaways: A weeklong culinary camp teaches children with CKD how to prepare kidney-friendly dishes. Local partnerships and having a “champion” in your institution can help to maintain a community program. To help children with chronic kidney disease better understand diet and nutrition, one pediatric nephrology center has created a free culinary camp to capitalize on kids’ love for food.
Open in Who Shared Issue with article?

TRACK trial: Low-dose rivaroxaban fails to reduce CV risks for patients with advanced CKD

|
By Lucas Laboy, Richard Smith, Manish Sood
| Citeline Verified
Key takeaways: Risks for major bleeding were significantly higher among the rivaroxaban group vs. placebo. Dedicated trials assessing CV risks for patients with CKD are needed, the researchers wrote. Treatment with low-dose rivaroxaban did not reduce risks for adverse CV events and increased risks for major bleeding among patients with advanced chronic kidney disease, according to data published in JAMA.
Open in Who Shared Issue with article?

TRACK trial: Low-dose rivaroxaban fails to reduce CV risks for patients with advanced CKD

|
By Lucas Laboy, Richard Smith, Manish Sood
| Citeline Verified
Key takeaways: Risks for major bleeding were significantly higher among the rivaroxaban group vs. placebo. Dedicated trials assessing CV risks for patients with CKD are needed, the researchers wrote. Treatment with low-dose rivaroxaban did not reduce risks for adverse CV events and increased risks for major bleeding among patients with advanced chronic kidney disease, according to data published in JAMA.
Open in Who Shared Issue with article?
See all 2,438 licensed articles (2,504 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified